Page 16 - Precigen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results - Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic - - Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs - - Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence and clinical activity - - A PRGN-3006 UltraCAR-T patient achieved complete remission with incomplete hematologic recovery (CRi) per ELN criteria - - Initiat...

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release fourth quarter and full year 2020 financial results after the market closes on Monday, March 1, 2021. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

Share this article Share this article GERMANTOWN, Md., Jan. 13, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented clinical and preclinical updates at the 39th Annual J.P. Morgan Healthcare Conference.  Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2020 clinical achievements and set forth Precigen's clinical goals for 2021. In addition to reviewing the latest clinical updates for Precigen's PRGN-3005 UltraCAR-T, ...